United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the United States over cancer risks associated with its now-discontinued heartburn drug Zantac, the Financial Times reported on Thursday.

Pfizer offers up to $250 mln to settle thousands of Zantac cancer lawsuits, FT reports

Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear.

Pfizer: Best Trading Momentum Since 2021 And 6% Yield

CRISPR Therapeutics

The healthcare sector has attractive stocks for any investment strategy. Pfizer has an impressive product pipeline and an attractive valuation as well.

2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential

Eli Lilly

Novo Nordisk

Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smaller biotech stocks out there, many of whom depend on just a handful of pipeline candidates.

Biotech Behemoths: 3 Giants Set to Dominate the Health Scene

16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO , May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews.

Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting

Hims & Hers Health

Starbucks

Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, others could use them to express their predictions on a particular stock.

3 Stocks That Suddenly Drew in Options Traders

Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25. However, recent developments suggest a potential turnaround for the pharmaceutical giant.

Pfizer's next move: Can it break above $30?

For years, Pfizer's dividend yield averaged roughly 3.6%. Following a prolonged share price slide, the dividend yield is now approaching 6%.

Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock

AstraZeneca

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn't recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.

A Struggling Pfizer Looks for Help From a Wall Streeter

Bristol-Myers

Bristol Myers and Pfizer have experienced declining sales lately. However, both companies are rejuvenating their lineups.

2 Beaten-Down Stocks to Buy and Hold for 10 Years

Bank of Nova Scotia

British American Tobacco

Enbridge

Enterprise Products Partners

Main Street Capital

Altria

MPLX

TC Energy

Vici Properties

High-yield dividend investing is a popular retirement strategy for its steady income, lower volatility, and potential to outperform the market. JPMorgan Equity Premium Income ETF offers an 8% yield but lacks dividend growth. Over a standard retirement, inflation is expected to be more than 100%. By combining JEPI with a portfolio of 10 blue-chip stocks yielding 7%, investors can achieve an 8% yield with stronger long-term dividend growth potential.

How To Build An 8% Yielding SWAN Portfolio With 10 Blue Chips

Merck

Teladoc

A commonly used strategy for investing is sector rotation. This involves the movement of funds from one sector to another based on macroeconomic and other factors.

The 3 Most Undervalued Healthcare Stocks to Buy in May 2024

Coca-Cola

Kroger

An investor needs to be looking for stocks that can ride out a period of general downturn in the market. Three key players come to mind, each offering its own investment opportunity as a store of value in turbulent market environments.

Safeguard Your Future: Top 3 Stocks to Weather Any Market Downturn

APA Corporation

Cisco Systems

Undervalued dividend stocks present two return routes: price appreciation or dividend payments that add to income. As of this writing, the market has some attractive dividend opportunities you buy.

3 Profitable Dividend Stocks to Buy at Near-Lows

Altimmune

Amgen

Structure Therapeutics Inc

Viking Therapeutics

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

AT&T

Dividend stocks have delivered the bulk of U.S. stock market returns since 1960. AT&T and Pfizer stand out as incredible bargains for income and value investors alike.

2 No-Brainer Dividend Stocks to Buy in May

Shares of Pfizer offer a 6% dividend yield at recent prices. The pharmaceutical giant has raised its quarterly payout for 15 consecutive years.

This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream

The lawsuits were filed in state courts nationwide, but the agreements don't completely resolve Pfizer's exposure to claims linking Zantac and cancer.

Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer

Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?

Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?

Pfizer's stock has experienced significant fluctuations in the past 4 years, with opportunities for investors to buy low and sell high. The market has driven Pfizer's price to a 10-year low. Pfizer's focus on oncology and its strong pipeline of new products position the company for future growth, although debt obligations may limit dividend increases in the short term.

Pfizer: A 6% Yield And At 10-Year Lows

Pfizer Inc has agreed to settle more than 10,000 cases about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal.

Pfizer agrees to settle more than 10,000 Zantac cancer lawsuits - Bloomberg News

Abbott Labs

Johnson & Johnson

Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.

Here's why you should buy these 3 stocks and hold them forever

Johnson & Johnson is a steady portfolio stalwart. Abbott Labs has exciting growth opportunities ahead.

News for Pfizer Stock (PFE)